# Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

> **NCT05311618** · PHASE1 · UNKNOWN · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 71 (estimated)

## Conditions studied

- Pancreatic Cancer
- Breast Cancer
- Gastric Cancer
- Non Small Cell Lung Cancer
- Cervical Cancer
- Endocervical Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Urothelial Cancer
- Colorectal Cancer
- Esophageal Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Melanoma
- Mesothelioma
- Cholangiocarcinoma

## Interventions

- **DRUG:** NGM438
- **DRUG:** Pembrolizumab (KEYTRUDA ®)

## Key facts

- **NCT ID:** NCT05311618
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-11
- **Primary completion:** 2025-04
- **Final completion:** 2025-06
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2024-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05311618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05311618, "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05311618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*